<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01382212</url>
  </required_header>
  <id_info>
    <org_study_id>M11-612</org_study_id>
    <secondary_id>2013-002610-13</secondary_id>
    <nct_id>NCT01382212</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis</brief_title>
  <official_title>A Phase 3, Open-Label, Multicenter Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie (prior sponsor, Abbott)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to evaluate the safety of paricalcitol capsules in pediatric subjects, ages
      10 to 16 years old, with Stage 5 chronic kidney disease (kidney failure) receiving peritoneal
      dialysis or hemodialysis and being treated for secondary hyperparathyroidism. Subjects will
      be in the dosing period of the study for 12 weeks in order to evaluate the incidence of
      hypercalcemia (high calcium levels in blood). Approximately 12 subjects will be enrolled and
      all 12 will receive paricalcitol capsules.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects With Hypercalcemia</measure>
    <time_frame>Day 1 to Week 12</time_frame>
    <description>The percentage of subjects with hypercalcemia, defined as at least 2 consecutive post-baseline corrected calcium values &gt; 10.2 mg/dL (2.55 mmol/L).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With 2 Consecutive Intact Parathyroid Hormone (iPTH)/120 Between 150 and 300 pg/mL</measure>
    <time_frame>Baseline (last measurement collected prior to the first dose) to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With 2 Consecutive iPTH Reductions of at Least 30% From Baseline</measure>
    <time_frame>Baseline (last measurement collected prior to the first dose) to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin: Mean Change From Baseline to Final Visit</measure>
    <time_frame>Baseline (last measurement collected prior to the first dose) to Final Visit (up to Week 12)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematocrit: Mean Change From Baseline to Final Visit</measure>
    <time_frame>Baseline (last measurement collected prior to the first dose) to Final Visit (up to Week 12)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Red Blood Cells: Mean Change From Baseline to Final Visit</measure>
    <time_frame>Baseline (last measurement collected prior to the first dose) to Final Visit (up to Week 12)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>White Blood Cells (WBC) and Platelet Count: Mean Change From Baseline to Final Visit</measure>
    <time_frame>Baseline (last measurement collected prior to the first dose) to Final Visit (up to Week 12)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutrophils, Lymphocytes, Monocytes, Eosinophils, and Basophils: Mean Change From Baseline to Final Visit</measure>
    <time_frame>Baseline (last measurement collected prior to the first dose) to Final Visit (up to Week 12)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Lactic Dehydrogenase (LDH), and Bone-Specific Alkaline Phosphatase (BSAP): Mean Change From Baseline to Final Visit</measure>
    <time_frame>Baseline (last measurement collected prior to the first dose) to Final Visit (up to Week 12)</time_frame>
    <description>n=subjects with evaluable Baseline and Post-baseline data for each parameter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bilirubin, Blood Urea Nitrogen (BUN), Uric Acid, Magnesium, Glucose, Cholesterol, Triglycerides, High Sensitivity C-Reactive Protein (hsCRP), Inorganic Phosphate, Corrected Calcium, and Creatinine: Mean Change From Baseline to Final Visit</measure>
    <time_frame>Baseline (last measurement collected prior to the first dose) to Final Visit (up to Week 12)</time_frame>
    <description>n=subjects with evaluable Baseline and Post-baseline data for each parameter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alkaline Phosphatase: Mean Change From Baseline to Final Visit</measure>
    <time_frame>Baseline (last measurement collected prior to the first dose) to Final Visit (up to Week 12)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sodium, Potassium, Chloride, Bicarbonate: Mean Change From Baseline to Final Visit</measure>
    <time_frame>Baseline (last measurement collected prior to the first dose) to Final Visit (up to Week 12)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Protein and Albumin: Mean Change From Baseline to Final Visit</measure>
    <time_frame>Baseline (last measurement collected prior to the first dose) to Final Visit (up to Week 12)</time_frame>
    <description>n=subjects with evaluable Baseline and Post-baseline data for each parameter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibroblast Growth Factor-23 (FGF-23), 1,25-Hydroxy Vitamin D, 25-Hydroxy Vitamin D, and Intact Parathyroid Hormone (iPTH): Mean Change From Baseline to Final Visit</measure>
    <time_frame>Baseline (last measurement collected prior to the first dose) to Final Visit (up to Week 12)</time_frame>
    <description>n=subjects with evaluable Baseline and Post-baseline data for each parameter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Osteocalcin: Mean Change From Baseline to Final Visit</measure>
    <time_frame>Baseline (last measurement collected prior to the first dose) to Final Visit (up to Week 12)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Adverse Events</measure>
    <time_frame>From first dose of study drug until 30 days following last dose of study drug (up to 16 weeks).</time_frame>
    <description>An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the subject and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent events (TEAEs/TESAEs) are defined as any event that began or worsened in severity after the first dose of study drug. For more details on adverse events please see the Adverse Event section.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Potentially Clinically Significant Electrocardiogram (ECG) Findings</measure>
    <time_frame>Baseline (Day 1) to Final Visit (up to Week 12)</time_frame>
    <description>12-lead ECGs were recorded after the subject had been in the supine position for at least 5 minutes. The number of subjects with potentially clinically significant ECG findings, as determined by the investigator, is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP): Mean Change From Baseline to Final Visit</measure>
    <time_frame>Baseline (last measurement collected prior to the first dose) to Final Visit (up to Week 12)</time_frame>
    <description>Blood pressure was measured after the subject had been sitting for at least 3 minutes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate: Mean Change From Baseline to Final Visit</measure>
    <time_frame>Baseline (last measurement collected prior to the first dose) to Final Visit (up to Week 12)</time_frame>
    <description>Heart rate was measured after the subject had been sitting for at least 3 minutes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral Body Temperature: Mean Change From Baseline to Final Visit</measure>
    <time_frame>Baseline (last measurement collected prior to the first dose) to Final Visit (up to Week 12)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Potentially Clinically Significant Physical Examination Findings</measure>
    <time_frame>Baseline (Day 1) and Final Visit (up to Week 12)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>End-Stage Renal Disease</condition>
  <condition>Secondary Hyperparathyroidism</condition>
  <arm_group>
    <arm_group_label>Paricalcitol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open-label paricalcitol (maximum dose of 16 µg), 3 times weekly (no more frequently than every other day) for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paricalcitol</intervention_name>
    <description>Paricalcitol soft capsule. Starting dose of paricalcitol was determined by the intact parathyroid hormone (iPTH) value (iPTH/120) from prior to Day 1, rounded down to the nearest whole number, not to exceed 16 µg 3 times weekly, no more frequently than every other day. Decisions to hold, maintain, increase, or decrease a dose were based on the iPTH, phosphorus, and calcium results generated from the most recent visit and within target Kidney Dialysis Outcomes Quality Initiatives (KDOQI) levels.</description>
    <arm_group_label>Paricalcitol</arm_group_label>
    <other_name>ABT-358, Zemplar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must be receiving peritoneal dialysis or hemodialysis for at least 3 months
             prior to Screening

          -  Subject is currently being diagnosed and/or treated for secondary hyperparathyroidism

          -  For entry into the Dosing Period (for subjects that are naïve to Vitamin D Receptor
             [VDR] Activators or those who have completed a 2 to 12 week washout), the subject must
             meet the following laboratory criteria prior to enrollment:

               -  A corrected calcium value ≥ 8.2 and ≤ 10.4 mg/dL

               -  A phosphorus value ≤ 6.5 mg/dL

               -  An intact parathyroid hormone (iPTH) value &gt; 300 pg/mL and less ≤ 2000 pg/mL

        Exclusion Criteria:

          -  Subject is expected or scheduled to receive a living donor kidney transplant within 3
             months of Screening or is a kidney transplant patient requiring full immunosuppressant
             therapy

          -  Subject is expected to stop peritoneal dialysis or hemodialysis within 4 months of
             Screening (per investigator discretion)

          -  Subject has had a parathyroidectomy within 12 weeks prior to Screening

          -  Subject has had symptomatic or significant hypocalcemia requiring VDR Activator
             therapy (i.e., calcitriol, paricalcitol, or doxercalciferol) within 2 months prior to
             Screening

          -  Subject is taking maintenance calcitonin, bisphosphonates, glucocorticoids in an
             equivalent dose of greater than 5 mg prednisone daily, or other drugs known to affect
             calcium or bone metabolism within 4 to 8 weeks prior to Dosing

          -  Subject is receiving cinacalcet at the time of Screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ann Eldred, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <removed_countries>
    <country>Germany</country>
    <country>Portugal</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.rxabbvie.com</url>
    <description>Prescribing Information</description>
  </link>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2011</study_first_submitted>
  <study_first_submitted_qc>June 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2011</study_first_posted>
  <results_first_submitted>September 16, 2016</results_first_submitted>
  <results_first_submitted_qc>November 8, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 21, 2016</results_first_posted>
  <disposition_first_submitted>April 22, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>April 22, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 23, 2016</disposition_first_posted>
  <last_update_submitted>November 8, 2016</last_update_submitted>
  <last_update_submitted_qc>November 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Evaluate safety through the evaluation of the incidence of hypercalcemia in pediatric subjects</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Secondary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ergocalciferols</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 26 subjects were screened and 13 pediatric subjects (between 10 and 16 years of age) were enrolled; 1 subject was 16 years of age at the time of Screening and turned 17 by the time treatment began.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Paricalcitol</title>
          <description>Open-label paricalcitol (maximum dose of 16 µg), 3 times weekly (no more frequently than every other day) for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Kidney transplant</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Paricalcitol</title>
          <description>Open-label paricalcitol (maximum dose of 16 µg), 3 times weekly (no more frequently than every other day) for 12 weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.5" spread="1.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With Hypercalcemia</title>
        <description>The percentage of subjects with hypercalcemia, defined as at least 2 consecutive post-baseline corrected calcium values &gt; 10.2 mg/dL (2.55 mmol/L).</description>
        <time_frame>Day 1 to Week 12</time_frame>
        <population>All-treated data set: all subjects enrolled and administered at least 1 dose of paricalcitol</population>
        <group_list>
          <group group_id="O1">
            <title>Paricalcitol</title>
            <description>Open-label paricalcitol (maximum dose of 16 µg), 3 times weekly (no more frequently than every other day) for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Hypercalcemia</title>
          <description>The percentage of subjects with hypercalcemia, defined as at least 2 consecutive post-baseline corrected calcium values &gt; 10.2 mg/dL (2.55 mmol/L).</description>
          <population>All-treated data set: all subjects enrolled and administered at least 1 dose of paricalcitol</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.3" lower_limit="1.9" upper_limit="45.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With 2 Consecutive Intact Parathyroid Hormone (iPTH)/120 Between 150 and 300 pg/mL</title>
        <time_frame>Baseline (last measurement collected prior to the first dose) to Week 12</time_frame>
        <population>All-treated data set</population>
        <group_list>
          <group group_id="O1">
            <title>Paricalcitol</title>
            <description>Open-label paricalcitol (maximum dose of 16 µg), 3 times weekly (no more frequently than every other day) for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With 2 Consecutive Intact Parathyroid Hormone (iPTH)/120 Between 150 and 300 pg/mL</title>
          <population>All-treated data set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.5" lower_limit="13.9" upper_limit="68.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With 2 Consecutive iPTH Reductions of at Least 30% From Baseline</title>
        <time_frame>Baseline (last measurement collected prior to the first dose) to Week 12</time_frame>
        <population>All-treated data set</population>
        <group_list>
          <group group_id="O1">
            <title>Paricalcitol</title>
            <description>Open-label paricalcitol (maximum dose of 16 µg), 3 times weekly (no more frequently than every other day) for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With 2 Consecutive iPTH Reductions of at Least 30% From Baseline</title>
          <population>All-treated data set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.5" lower_limit="31.6" upper_limit="86.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemoglobin: Mean Change From Baseline to Final Visit</title>
        <time_frame>Baseline (last measurement collected prior to the first dose) to Final Visit (up to Week 12)</time_frame>
        <population>All subjects in the all-treated data set with evaluable data</population>
        <group_list>
          <group group_id="O1">
            <title>Paricalcitol</title>
            <description>Open-label paricalcitol (maximum dose of 16 µg), 3 times weekly (no more frequently than every other day) for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoglobin: Mean Change From Baseline to Final Visit</title>
          <population>All subjects in the all-treated data set with evaluable data</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="1.263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hematocrit: Mean Change From Baseline to Final Visit</title>
        <time_frame>Baseline (last measurement collected prior to the first dose) to Final Visit (up to Week 12)</time_frame>
        <population>All subjects in the all-treated data set with evaluable data</population>
        <group_list>
          <group group_id="O1">
            <title>Paricalcitol</title>
            <description>Open-label paricalcitol (maximum dose of 16 µg), 3 times weekly (no more frequently than every other day) for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Hematocrit: Mean Change From Baseline to Final Visit</title>
          <population>All subjects in the all-treated data set with evaluable data</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.08" spread="5.066"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Red Blood Cells: Mean Change From Baseline to Final Visit</title>
        <time_frame>Baseline (last measurement collected prior to the first dose) to Final Visit (up to Week 12)</time_frame>
        <population>All subjects in the all-treated data set with evaluable data</population>
        <group_list>
          <group group_id="O1">
            <title>Paricalcitol</title>
            <description>Open-label paricalcitol (maximum dose of 16 µg), 3 times weekly (no more frequently than every other day) for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Red Blood Cells: Mean Change From Baseline to Final Visit</title>
          <population>All subjects in the all-treated data set with evaluable data</population>
          <units>cells x 10^6/µL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" spread="0.496"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>White Blood Cells (WBC) and Platelet Count: Mean Change From Baseline to Final Visit</title>
        <time_frame>Baseline (last measurement collected prior to the first dose) to Final Visit (up to Week 12)</time_frame>
        <population>All subjects in the all-treated data set with evaluable data</population>
        <group_list>
          <group group_id="O1">
            <title>Paricalcitol</title>
            <description>Open-label paricalcitol (maximum dose of 16 µg), 3 times weekly (no more frequently than every other day) for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>White Blood Cells (WBC) and Platelet Count: Mean Change From Baseline to Final Visit</title>
          <population>All subjects in the all-treated data set with evaluable data</population>
          <units>cells x 10^3/µL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>WBC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="2.982"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet Count</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.2" spread="47.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neutrophils, Lymphocytes, Monocytes, Eosinophils, and Basophils: Mean Change From Baseline to Final Visit</title>
        <time_frame>Baseline (last measurement collected prior to the first dose) to Final Visit (up to Week 12)</time_frame>
        <population>All subjects in the all-treated data set with evaluable data</population>
        <group_list>
          <group group_id="O1">
            <title>Paricalcitol</title>
            <description>Open-label paricalcitol (maximum dose of 16 µg), 3 times weekly (no more frequently than every other day) for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Neutrophils, Lymphocytes, Monocytes, Eosinophils, and Basophils: Mean Change From Baseline to Final Visit</title>
          <population>All subjects in the all-treated data set with evaluable data</population>
          <units>cells x 10^9/µL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Neutrophils</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="2.6812"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.294" spread="0.597"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.032" spread="0.1276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.059" spread="0.1522"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.0322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Lactic Dehydrogenase (LDH), and Bone-Specific Alkaline Phosphatase (BSAP): Mean Change From Baseline to Final Visit</title>
        <description>n=subjects with evaluable Baseline and Post-baseline data for each parameter.</description>
        <time_frame>Baseline (last measurement collected prior to the first dose) to Final Visit (up to Week 12)</time_frame>
        <population>All subjects in the all-treated data set with evaluable data</population>
        <group_list>
          <group group_id="O1">
            <title>Paricalcitol</title>
            <description>Open-label paricalcitol (maximum dose of 16 µg), 3 times weekly (no more frequently than every other day) for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Lactic Dehydrogenase (LDH), and Bone-Specific Alkaline Phosphatase (BSAP): Mean Change From Baseline to Final Visit</title>
          <description>n=subjects with evaluable Baseline and Post-baseline data for each parameter.</description>
          <population>All subjects in the all-treated data set with evaluable data</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT (n=11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.55" spread="16.501"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST (n=11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.45" spread="12.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDH (n=11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.5" spread="33.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BSAP (n=9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49.4" spread="86.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bilirubin, Blood Urea Nitrogen (BUN), Uric Acid, Magnesium, Glucose, Cholesterol, Triglycerides, High Sensitivity C-Reactive Protein (hsCRP), Inorganic Phosphate, Corrected Calcium, and Creatinine: Mean Change From Baseline to Final Visit</title>
        <description>n=subjects with evaluable Baseline and Post-baseline data for each parameter.</description>
        <time_frame>Baseline (last measurement collected prior to the first dose) to Final Visit (up to Week 12)</time_frame>
        <population>All subjects in the all-treated data set with evaluable data</population>
        <group_list>
          <group group_id="O1">
            <title>Paricalcitol</title>
            <description>Open-label paricalcitol (maximum dose of 16 µg), 3 times weekly (no more frequently than every other day) for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Bilirubin, Blood Urea Nitrogen (BUN), Uric Acid, Magnesium, Glucose, Cholesterol, Triglycerides, High Sensitivity C-Reactive Protein (hsCRP), Inorganic Phosphate, Corrected Calcium, and Creatinine: Mean Change From Baseline to Final Visit</title>
          <description>n=subjects with evaluable Baseline and Post-baseline data for each parameter.</description>
          <population>All subjects in the all-treated data set with evaluable data</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total bilirubin (n=11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.032" spread="0.3165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct Bilirubin (n=11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.013" spread="0.0785"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Indirect Bilirubin (n=9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.056" spread="0.3035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN (n=11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" spread="11.614"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric Acid (n=11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.31" spread="1.245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Magnesium (n=11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.082" spread="0.3649"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose (n=11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.36" spread="10.172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol (n=11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.4" spread="27.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides (n=11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2" spread="40.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hsCRP (n=11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.061" spread="0.1967"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inorganic phosphate (n=13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.64" spread="1.188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Corrected Calcium (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.31" spread="0.421"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine (n=11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48" spread="1.592"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alkaline Phosphatase: Mean Change From Baseline to Final Visit</title>
        <time_frame>Baseline (last measurement collected prior to the first dose) to Final Visit (up to Week 12)</time_frame>
        <population>All subjects in the all-treated data set with evaluable data</population>
        <group_list>
          <group group_id="O1">
            <title>Paricalcitol</title>
            <description>Open-label paricalcitol (maximum dose of 16 µg), 3 times weekly (no more frequently than every other day) for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Alkaline Phosphatase: Mean Change From Baseline to Final Visit</title>
          <population>All subjects in the all-treated data set with evaluable data</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-61.8" spread="117.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sodium, Potassium, Chloride, Bicarbonate: Mean Change From Baseline to Final Visit</title>
        <time_frame>Baseline (last measurement collected prior to the first dose) to Final Visit (up to Week 12)</time_frame>
        <population>All subjects in the all-treated data set with evaluable data</population>
        <group_list>
          <group group_id="O1">
            <title>Paricalcitol</title>
            <description>Open-label paricalcitol (maximum dose of 16 µg), 3 times weekly (no more frequently than every other day) for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Sodium, Potassium, Chloride, Bicarbonate: Mean Change From Baseline to Final Visit</title>
          <population>All subjects in the all-treated data set with evaluable data</population>
          <units>mEq/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sodium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="2.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.746"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="3.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.45" spread="3.446"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Protein and Albumin: Mean Change From Baseline to Final Visit</title>
        <description>n=subjects with evaluable Baseline and Post-baseline data for each parameter.</description>
        <time_frame>Baseline (last measurement collected prior to the first dose) to Final Visit (up to Week 12)</time_frame>
        <population>All-treated data set</population>
        <group_list>
          <group group_id="O1">
            <title>Paricalcitol</title>
            <description>Open-label paricalcitol (maximum dose of 16 µg), 3 times weekly (no more frequently than every other day) for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Protein and Albumin: Mean Change From Baseline to Final Visit</title>
          <description>n=subjects with evaluable Baseline and Post-baseline data for each parameter.</description>
          <population>All-treated data set</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total protein (n=11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin (n=13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fibroblast Growth Factor-23 (FGF-23), 1,25-Hydroxy Vitamin D, 25-Hydroxy Vitamin D, and Intact Parathyroid Hormone (iPTH): Mean Change From Baseline to Final Visit</title>
        <description>n=subjects with evaluable Baseline and Post-baseline data for each parameter.</description>
        <time_frame>Baseline (last measurement collected prior to the first dose) to Final Visit (up to Week 12)</time_frame>
        <population>All-treated data set</population>
        <group_list>
          <group group_id="O1">
            <title>Paricalcitol</title>
            <description>Open-label paricalcitol (maximum dose of 16 µg), 3 times weekly (no more frequently than every other day) for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Fibroblast Growth Factor-23 (FGF-23), 1,25-Hydroxy Vitamin D, 25-Hydroxy Vitamin D, and Intact Parathyroid Hormone (iPTH): Mean Change From Baseline to Final Visit</title>
          <description>n=subjects with evaluable Baseline and Post-baseline data for each parameter.</description>
          <population>All-treated data set</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FGF-23 (n=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1990.7" spread="3317.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1,25-Hydroxy Vitamin D (n=11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.65" spread="29.296"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25-Hydroxy Vitamin D (n=11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" spread="10.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>iPTH (n=13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-437.5" spread="491.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Osteocalcin: Mean Change From Baseline to Final Visit</title>
        <time_frame>Baseline (last measurement collected prior to the first dose) to Final Visit (up to Week 12)</time_frame>
        <population>All subjects in the all-treated data set with evaluable data</population>
        <group_list>
          <group group_id="O1">
            <title>Paricalcitol</title>
            <description>Open-label paricalcitol (maximum dose of 16 µg), 3 times weekly (no more frequently than every other day) for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Osteocalcin: Mean Change From Baseline to Final Visit</title>
          <population>All subjects in the all-treated data set with evaluable data</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117.21" spread="223.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Adverse Events</title>
        <description>An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the subject and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent events (TEAEs/TESAEs) are defined as any event that began or worsened in severity after the first dose of study drug. For more details on adverse events please see the Adverse Event section.</description>
        <time_frame>From first dose of study drug until 30 days following last dose of study drug (up to 16 weeks).</time_frame>
        <population>All-treated data set</population>
        <group_list>
          <group group_id="O1">
            <title>Paricalcitol</title>
            <description>Open-label paricalcitol (maximum dose of 16 µg), 3 times weekly (no more frequently than every other day) for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Adverse Events</title>
          <description>An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the subject and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent events (TEAEs/TESAEs) are defined as any event that began or worsened in severity after the first dose of study drug. For more details on adverse events please see the Adverse Event section.</description>
          <population>All-treated data set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TESAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Potentially Clinically Significant Electrocardiogram (ECG) Findings</title>
        <description>12-lead ECGs were recorded after the subject had been in the supine position for at least 5 minutes. The number of subjects with potentially clinically significant ECG findings, as determined by the investigator, is presented.</description>
        <time_frame>Baseline (Day 1) to Final Visit (up to Week 12)</time_frame>
        <population>All-treated data set</population>
        <group_list>
          <group group_id="O1">
            <title>Paricalcitol</title>
            <description>Open-label paricalcitol (maximum dose of 16 µg), 3 times weekly (no more frequently than every other day) for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Potentially Clinically Significant Electrocardiogram (ECG) Findings</title>
          <description>12-lead ECGs were recorded after the subject had been in the supine position for at least 5 minutes. The number of subjects with potentially clinically significant ECG findings, as determined by the investigator, is presented.</description>
          <population>All-treated data set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP): Mean Change From Baseline to Final Visit</title>
        <description>Blood pressure was measured after the subject had been sitting for at least 3 minutes.</description>
        <time_frame>Baseline (last measurement collected prior to the first dose) to Final Visit (up to Week 12)</time_frame>
        <population>All-treated data set</population>
        <group_list>
          <group group_id="O1">
            <title>Paricalcitol</title>
            <description>Open-label paricalcitol (maximum dose of 16 µg), 3 times weekly (no more frequently than every other day) for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP): Mean Change From Baseline to Final Visit</title>
          <description>Blood pressure was measured after the subject had been sitting for at least 3 minutes.</description>
          <population>All-treated data set</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread="15.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="12.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heart Rate: Mean Change From Baseline to Final Visit</title>
        <description>Heart rate was measured after the subject had been sitting for at least 3 minutes.</description>
        <time_frame>Baseline (last measurement collected prior to the first dose) to Final Visit (up to Week 12)</time_frame>
        <population>All-treated data set</population>
        <group_list>
          <group group_id="O1">
            <title>Paricalcitol</title>
            <description>Open-label paricalcitol (maximum dose of 16 µg), 3 times weekly (no more frequently than every other day) for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Rate: Mean Change From Baseline to Final Visit</title>
          <description>Heart rate was measured after the subject had been sitting for at least 3 minutes.</description>
          <population>All-treated data set</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="17.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oral Body Temperature: Mean Change From Baseline to Final Visit</title>
        <time_frame>Baseline (last measurement collected prior to the first dose) to Final Visit (up to Week 12)</time_frame>
        <population>All-treated data set</population>
        <group_list>
          <group group_id="O1">
            <title>Paricalcitol</title>
            <description>Open-label paricalcitol (maximum dose of 16 µg), 3 times weekly (no more frequently than every other day) for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Oral Body Temperature: Mean Change From Baseline to Final Visit</title>
          <population>All-treated data set</population>
          <units>degrees Celsius</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Potentially Clinically Significant Physical Examination Findings</title>
        <time_frame>Baseline (Day 1) and Final Visit (up to Week 12)</time_frame>
        <population>All-treated data set</population>
        <group_list>
          <group group_id="O1">
            <title>Paricalcitol</title>
            <description>Open-label paricalcitol (maximum dose of 16 µg), 3 times weekly (no more frequently than every other day) for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Potentially Clinically Significant Physical Examination Findings</title>
          <population>All-treated data set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-emergent adverse events were collected from first dose of study drug until 30 days following last dose of study drug (up to 16 weeks); serious adverse events were collected from the time when informed consent was obtained (up to 28 weeks).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Paricalcitol</title>
          <description>Open-label paricalcitol (maximum dose of 16 μg), 3 times weekly (no more frequently than every other day) for 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>PERITONEAL DIALYSIS COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>FLUID OVERLOAD</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>INFLUENZA LIKE ILLNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ARTERIOVENOUS FISTULA SITE COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>PROCEDURAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>PROCEDURAL VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>BLOOD CALCIUM INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>HAEMOGLOBIN DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERPHOSPHATAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>THROAT IRRITATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The sample size of the study was limited to 13 subjects and there was no comparator group, so the study was not designed to analyze efficacy.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Global Medical Information</name_or_title>
      <organization>AbbVie</organization>
      <phone>800-633-9110</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

